List of Excipients in Branded Drug MIACALCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Institutional LLC	MIACALCIN	calcitonin salmon	67457-675	ACETIC ACID
Mylan Institutional LLC	MIACALCIN	calcitonin salmon	67457-675	PHENOL
Mylan Institutional LLC	MIACALCIN	calcitonin salmon	67457-675	SODIUM ACETATE
Mylan Institutional LLC	MIACALCIN	calcitonin salmon	67457-675	SODIUM CHLORIDE
Mylan Institutional LLC	MIACALCIN	calcitonin salmon	67457-675	WATER

Miacalcin Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 12, 2026

Miacalcin is a salmon calcitonin product historically marketed as an injection and nasal spray for postmenopausal osteoporosis, Paget's disease of bone, and hypercalcemia. Its active ingredient is an established peptide with limited remaining composition-of-matter protection. Commercial value therefore depends more on formulation performance, device execution, regulatory strategy, supply reliability, and differentiated delivery than on exclusivity around salmon calcitonin itself.

The most attractive excipient opportunities are in nasal absorption, preservative reduction, peptide stabilization, multidose-device compatibility, and patient-friendly alternatives to injectable administration. The principal commercial constraint is the narrow therapeutic and market position of calcitonin relative to bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab.

What is Miacalcin and which formulations have been marketed?

Miatcalcin is the brand name associated with synthetic salmon calcitonin. Salmon calcitonin is a 32-amino-acid peptide that acts primarily through the calcitonin receptor and reduces osteoclast-mediated bone resorption.

Product	Route	Historical strength	Principal formulation context
Miacalcin injection	Subcutaneous or intramuscular	200 International Units/mL	Acidic acetate-buffered aqueous solution
Miacalcin nasal spray	Intranasal	200 International Units per actuation	Aqueous multidose spray with benzalkonium chloride preservative
Generic salmon calcitonin injection	Injectable	Product-specific	Similar peptide and aqueous-buffer strategy
Generic salmon calcitonin nasal spray	Intranasal	200 International Units per actuation	Product-specific spray pump and preservative system

The nasal spray was positioned as a less burdensome alternative to injections. The injection remained relevant for indications requiring parenteral administration, including hypercalcemia and selected acute clinical settings. FDA labeling identifies postmenopausal osteoporosis, Paget's disease, and hypercalcemia among the historical indications for salmon calcitonin products.[1,2]

What excipients are used in Miacalcin formulations?

The Miacalcin excipient strategy differs materially by route.

Miacalcin injection excipients

The injectable formulation uses a simple aqueous system centered on acetate buffering and isotonicity control. Public labeling identifies acetic acid, sodium acetate trihydrate, sodium chloride, and water for injection as formulation components.[1]

The functional roles are:

Excipient or component	Primary function
Acetic acid	Acidification and buffer control
Sodium acetate trihydrate	Acetate buffering
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle
Salmon calcitonin	Active peptide

The formulation is intentionally conservative. It avoids complex surfactant systems and relies on low-pH aqueous conditions, controlled ionic strength, sterile processing, and refrigerated storage.

Miacalcin nasal spray excipients

The nasal spray uses purified water, benzalkonium chloride, and pH-adjustment agents, with hydrochloric acid and sodium hydroxide used to establish the target pH.[2] Benzalkonium chloride acts primarily as a preservative in the multidose container.

The nasal formulation must manage several competing requirements:

1. Preserve peptide integrity during storage.
2. Maintain microbiological quality after repeated pump actuations.
3. Produce consistent dose delivery.
4. Avoid excessive nasal irritation.
5. Support absorption across the nasal mucosa.
6. Maintain spray-pump performance over the labeled in-use period.

Unlike a tablet, the nasal product cannot rely on high drug loading or a simple dissolution profile. Delivered dose, plume geometry, droplet size, pump priming, spray angle, and nasal deposition are central product-performance variables.

What formulation patents protect Miacalcin?

The principal Miacalcin formulation opportunities are more likely to involve route-specific delivery, stabilized peptide compositions, nasal absorption enhancement, and device compatibility than the underlying salmon calcitonin molecule.

The original salmon calcitonin product and its basic aqueous formulations are old. Any early composition-of-matter or basic formulation patents would generally have expired after the applicable patent term. Later patent activity in this area has typically focused on:

• Intranasal delivery systems.
• Absorption-enhancing excipients.
• Stabilized peptide formulations.
• Dry-powder or powder-inhalation systems.
• Mucoadhesive carriers.
• Preservative-free multidose devices.
• Unit-dose nasal containers.
• Combination products involving calcitonin and bone-health agents.
• Manufacturing processes that improve peptide purity or reduce aggregation.

A commercial review should separate three patent categories:

Patent category	Relevance to Miacalcin
Salmon calcitonin composition-of-matter patents	Low current blocking value because of age
Nasal formulation and absorption patents	Potentially relevant to differentiated follow-on products
Device and manufacturing patents	Potentially relevant to commercial launch and supply control

The FDA Orange Book should be reviewed for current patents listed against the specific NDA and dosage form. Historical brand patents may no longer create an effective barrier to a generic or 505(b)(2) product. A patent’s inclusion in a product’s historical estate does not establish current enforceability or commercial blocking power.

What is the Orange Book status of Miacalcin?

Miacalcin has been associated with FDA-approved NDAs for injection and nasal spray. The commercial significance of those approvals depends on whether the product remains actively marketed, whether the NDA is still listed as the reference product, and whether current Orange Book patent or exclusivity listings remain active.

The key regulatory distinctions are:

• An approved NDA can remain in FDA records after commercial discontinuation.
• A product may be discontinued for commercial reasons without being withdrawn for safety or efficacy.
• An ANDA applicant can rely on an eligible reference-listed drug even when the brand has limited current commercial presence, subject to FDA reference-product rules.
• An authorized generic or listed generic may alter the competitive landscape without changing the underlying patent position.

The historic Miacalcin products do not have the type of long-lived biologic exclusivity associated with monoclonal antibodies. Salmon calcitonin is a peptide drug, but the relevant regulatory pathway is not equivalent to the modern biosimilar pathway used for licensed biologics under the Public Health Service Act.

When does Miacalcin lose exclusivity?

Miacalcin’s practical exclusivity has largely expired. The product’s commercial protection is not based on a current new chemical entity exclusivity period. Any remaining barriers are more likely to arise from product-specific patents, regulatory reference-product issues, manufacturing complexity, or limited market economics.

Exclusivity element	Miacalcin position
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial significance identified
Orphan exclusivity	Not the principal historical protection
Core molecule patent protection	Expected to be expired
Formulation patents	Potentially relevant only if unexpired and claim scope is applicable
Device patents	Potentially relevant to specific spray systems
Regulatory exclusivity for a new reformulation	Possible for a qualifying new product, not an automatic right

A follow-on company would need to analyze the specific FDA reference product, current Orange Book listings, patent certifications, and any unlisted intellectual-property claims before selecting an ANDA, 505(b)(2), or other pathway.

How strong is the Miacalcin patent estate?

The legacy patent estate is weak as a broad exclusionary platform but may retain targeted value around nasal delivery and manufacturing.

Core patent strength

The core salmon calcitonin molecule is not a durable exclusivity asset. Multiple suppliers and generic manufacturers can potentially work with the same active ingredient if they satisfy identity, purity, potency, sterility, stability, and immunogenicity requirements.

Formulation patent strength

Formulation claims can be stronger when they require a specific combination of:

• Peptide concentration.
• pH range.
• Buffer composition.
• Preservative level.
• Absorption enhancer.
• Stability profile.
• Device configuration.
• Delivered-dose performance.

Broad claims to an aqueous salmon calcitonin solution are vulnerable to prior-art challenges. Narrow claims tied to a validated absorption enhancer, a specific preservative-free system, or a device-controlled plume may have greater commercial value.

Manufacturing patent strength

Manufacturing know-how may be more important than public patent claims. Salmon calcitonin production requires control of peptide synthesis, cleavage, folding where applicable, purification, oxidation, deamidation, aggregation, residual solvents, and microbial quality. A reliable supplier with a validated peptide process can create a practical barrier even when patent protection is limited.

What excipient strategies could create new commercial opportunities?

Preservative-free nasal spray

Benzalkonium chloride is effective for multidose preservation but can create concerns around nasal tolerability, epithelial effects, and chronic-use acceptability. A preservative-free system could use:

• Unit-dose containers.
• Sterile blow-fill-seal packaging.
• One-way valve systems.
• Low-bioburden manufacturing.
• Device designs that prevent backflow and contamination.

The opportunity is strongest if the product can demonstrate equivalent delivered dose, microbial robustness, and improved tolerability without raising manufacturing cost beyond the target market price.

Absorption-enhanced nasal delivery

Salmon calcitonin has low systemic bioavailability when delivered intranasally. Absorption enhancers can improve exposure, but the development burden includes local irritation, variable mucosal permeability, food-independent dosing behavior, and chronic-use tolerability.

Potential enhancer classes include:

• Bile-salt derivatives.
• Fatty-acid salts.
• Cyclodextrins.
• Mucoadhesive polymers.
• Chitosan-based systems.
• Surface-active agents.
• Enzyme-inhibition systems.

The commercial risk is that a higher systemic exposure does not automatically produce a clinically superior product. The developer must link pharmacokinetic improvement to a meaningful benefit in fracture prevention, bone turnover, acute hypercalcemia, or another approved or strategically selected indication.

Dry-powder nasal formulation

A dry powder may improve chemical stability and reduce dependence on aqueous preservatives. It may also permit lower shipping and storage costs. The development challenges include:

• Peptide aerosolization.
• Powder dispersibility.
• Nasal deposition.
• Humidity sensitivity.
• Dose uniformity.
• Device resistance and patient handling.
• Protection against aggregation and oxidation.

Dry-powder calcitonin could be attractive in markets with cold-chain limitations or in products seeking longer shelf life. It would likely require a new drug application or a 505(b)(2) strategy rather than a straightforward generic approach.

Injectable prefilled presentation

The injection’s excipient system is simple, but the presentation can be improved through:

• Prefilled syringes.
• Autoinjectors.
• Low-volume subcutaneous delivery.
• Ready-to-use cartridges.
• Reduced dead-space containers.
• Improved cold-chain packaging.

The commercial value is operational rather than pharmacological. A prefilled product may reduce preparation errors and administration burden in hypercalcemia or hospital use, but injectable salmon calcitonin competes against established hospital protocols and alternative therapies.

Stabilized liquid formulation

A stabilized liquid could target reduced aggregation, improved room-temperature handling, or longer in-use stability. Useful strategies may involve:

• Trehalose or sucrose.
• Polyols.
• Amino-acid stabilizers.
• Low-level nonionic surfactants.
• Chelating agents where compatible.
• Optimized acetate or citrate buffering.
• Oxygen-control packaging.

Each added excipient increases the burden of compatibility, extractables and leachables, toxicology, and regulatory justification. A simpler formulation with a strong stability package may have greater approval and manufacturing value than a heavily engineered system.

What regulatory pathway would apply to a new Miacalcin product?

The pathway depends on the extent of formulation and device change.

Product concept	Likely regulatory route
Same active ingredient, same route, equivalent dosage form	ANDA, if sameness and bioequivalence requirements are met
New nasal enhancer or materially different formulation	505(b)(2) may be appropriate
New device with the same drug formulation	ANDA or 505(b)(2), depending on formulation and performance differences
New indication	505(b)(2) or full NDA strategy
New long-acting injectable or implant	Likely 505(b)(2) or NDA
New biologic-style development strategy	Generally not the natural route for legacy salmon calcitonin

A 505(b)(2) product can rely partly on FDA findings for an approved product while supporting differences with new clinical, pharmacokinetic, local-tolerability, or device data. This pathway may be commercially preferable for an improved nasal system because it can support differentiated formulation claims that would be difficult to fit within a conventional ANDA.

Which companies are challenging Miacalcin?

The competitive field includes generic and specialty pharmaceutical companies capable of manufacturing peptide injectables or nasal products. Competition is likely to come from:

• Generic salmon calcitonin injection manufacturers.
• Generic nasal-spray manufacturers.
• Specialty companies with nasal-device capabilities.
• Contract development and manufacturing organizations.
• Developers of alternative osteoporosis therapies.

A complete company-by-company litigation map depends on current FDA listings and federal court records. The relevant diligence targets are ANDA applicants, Paragraph IV notices, Abbreviated New Drug Application litigation, and any settlement agreements involving the applicable Miacalcin NDA.

What Paragraph IV risks exist for Miacalcin?

Paragraph IV exposure is more likely for a currently listed patent covering a nasal formulation, device, or method of use than for the old salmon calcitonin molecule.

A generic applicant may certify that an Orange Book-listed patent is:

• Not infringed.
• Invalid.
• Unenforceable.
• Not eligible for listing.
• Not a barrier to the proposed product.

A Paragraph IV notice can trigger a 45-day patent-infringement filing period and, if litigation is filed, a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.[3] The practical significance depends on the patent’s expiration date, claim scope, regulatory exclusivity, and whether the product has meaningful sales.

For Miacalcin, the economic value of litigating a marginal formulation patent may be limited. A settlement can preserve a branded or authorized-generic position, but the bargaining leverage is lower when the reference product has declining demand and several therapeutic substitutes.

What patent litigation and settlement issues affect Miacalcin?

The likely litigation issues include:

• Whether the proposed nasal formulation falls within a specific pH or concentration claim.
• Whether a spray pump is covered by device claims.
• Whether a preservative-free product infringes claims directed to a multidose preserved formulation.
• Whether an absorption enhancer is chemically or functionally claimed.
• Whether method-of-use claims remain enforceable for a labeled indication.
• Whether the listed patent correctly belongs in the Orange Book.

Settlement agreements may address:

• Authorized generic timing.
• License dates.
• Launch at risk.
• Product supply.
• Patent carve-outs.
• Non-infringing formulation changes.
• Market entry by dosage form.

No broad conclusion about current Miacalcin litigation should be drawn from historical patent disputes involving salmon calcitonin products generally. Product-specific docket review is required for a current legal position.

What method-of-use patents protect salmon calcitonin?

Method-of-use claims may cover treatment of:

• Postmenopausal osteoporosis.
• Paget's disease.
• Hypercalcemia.
• Acute bone pain associated with vertebral compression fractures.
• Other bone-resorption or calcium-regulation conditions.

Older therapeutic uses are vulnerable to expiration and prior art. A method-of-use patent can still matter if the generic product label includes the protected indication. A carve-out may reduce infringement risk where FDA permits removal of the protected use from labeling. The commercial value of a method patent depends on whether the protected indication represents a material share of prescriptions.

Are biosimilar risks relevant to Miacalcin?

Traditional biosimilar competition is not the main risk. Salmon calcitonin is a peptide pharmaceutical rather than a monoclonal antibody or other large biologic typically associated with the U.S. biosimilar pathway.

The more relevant competitive risks are:

• ANDA-approved generic injection.
• ANDA-approved generic nasal spray.
• 505(b)(2) reformulations.
• Compounded or institutionally prepared alternatives where legally permissible.
• Substitution with non-calcitonin osteoporosis drugs.
• New delivery systems that reduce the commercial value of the legacy product.

A peptide product can still present complex analytical and manufacturing issues. Those issues may increase development cost without creating biologic-style exclusivity.

How does Miacalcin compare with competing bone drugs?

Miacalcin has a weaker current commercial position than most modern osteoporosis medicines.

Product class	Main advantage over Miacalcin	Main disadvantage
Oral bisphosphonates	Low cost and established fracture-prevention data	Adherence and gastrointestinal limitations
Intravenous bisphosphonates	Infrequent dosing	Infusion burden and renal considerations
Denosumab	Six-month dosing and strong antiresorptive efficacy	Injection and rebound bone-loss management
Teriparatide or abaloparatide	Anabolic bone formation	Cost and daily administration
Romosozumab	Monthly anabolic and antiresorptive activity	Cardiovascular risk considerations and restricted duration
Salmon calcitonin	Established peptide and nasal option	Lower efficacy, weaker market demand, and safety concerns in long-term osteoporosis use

FDA and international regulators have raised concerns about the limited benefit-risk profile of calcitonin for long-term osteoporosis treatment, including malignancy-signal concerns associated with prolonged exposure.[2,4] That limits the value of investing in a broad osteoporosis relaunch unless a new formulation produces a clear clinical or tolerability advantage.

What geographic opportunities exist for Miacalcin reformulation?

The strongest geographic opportunities are likely to be outside the most mature branded osteoporosis markets, particularly where:

• Injectable access is limited.
• Cold-chain infrastructure is constrained.
• Generic pricing is competitive but product availability is inconsistent.
• Nasal administration is preferred by patients.
• Hypercalcemia treatment remains dependent on injectable calcitonin.
• Regulatory agencies permit reliance on established foreign reference products.

A room-temperature-stable nasal powder or preservative-free unit-dose spray could improve distribution economics in emerging markets. However, the product must compete with low-cost generic injections and local regulatory requirements for peptide quality, device validation, and stability data.

What manufacturing and intellectual-property barriers remain?

The main practical barriers are technical rather than molecule-level patent barriers.

Peptide quality

Manufacturers must control:

• Sequence identity.
• Related peptides.
• Deamidation.
• Oxidation.
• Aggregates.
• Residual reagents.
• Endotoxin.
• Sterility for injectable products.
• Spray-device dose uniformity for nasal products.

Device integration

For nasal products, the pump is part of the product’s performance profile. The sponsor must validate:

• Actuation force.
• Priming and repriming.
• Delivered volume.
• Droplet or particle-size distribution.
• Container-closure integrity.
• Orientation effects.
• Temperature effects.
• End-of-container performance.

Supply-chain control

A commercial developer may obtain greater defensibility through:

• Dual-source peptide supply.
• Proprietary purification.
• Dedicated device tooling.
• Validated sterile filling.
• Controlled cold-chain logistics.
• Long-term excipient and packaging agreements.

These measures do not replace patents, but they can reduce substitution risk and support reliable supply contracts.

What revenue exposure and commercial opportunities exist?

Miacalcin-specific revenue exposure is difficult to assess from public product information because historical sales may be reported within broader osteoporosis or specialty pharmaceutical portfolios rather than as a separately disclosed line item.

The commercial opportunities fall into four categories:

1. A low-cost generic nasal spray with reliable supply.
2. A 505(b)(2) nasal product with improved tolerability or absorption.
3. A prefilled injectable for hospital and specialty use.
4. A reformulated product for a narrow indication such as acute hypercalcemia.

The largest opportunity is unlikely to be a broad osteoporosis relaunch. The more defensible strategy is a focused product with lower administration burden, improved stability, or a defined institutional use case.

Key Takeaways

• Miacalcin is salmon calcitonin marketed historically as an injection and nasal spray.
• The legacy molecule and basic formulation provide limited current patent protection.
• The nasal spray’s key excipients include benzalkonium chloride, water, and pH-adjustment agents.
• The injection uses an acetate-buffered aqueous system with sodium chloride for tonicity.
• Preservative-free nasal delivery, absorption enhancement, dry-powder systems, and prefilled injection devices are the leading excipient-driven opportunities.
• A 505(b)(2) pathway may be more suitable than an ANDA for materially improved nasal formulations.
• Paragraph IV risk depends on current Orange Book listings and any surviving formulation or device patents.
• Biosimilar competition is less relevant than generic and 505(b)(2) competition.
• Manufacturing controls, peptide purity, device performance, and supply reliability may create stronger practical barriers than legacy patents.
• The most credible commercial strategy is a targeted reformulation rather than a broad branded osteoporosis relaunch.

FAQs

Can benzalkonium chloride be removed from Miacalcin nasal spray?

Yes. A preservative-free product could use unit-dose packaging or a validated multidose contamination-control system. The product would need supporting data for sterility assurance, in-use stability, delivered dose, and nasal tolerability.

Is a salmon calcitonin dry-powder nasal product commercially viable?

It may be viable if it improves shelf life, reduces cold-chain dependence, and maintains consistent nasal deposition. The product would face substantial device, powder-engineering, clinical, and regulatory requirements.

Would a Miacalcin generic require clinical efficacy trials?

A conventional ANDA generally relies on pharmaceutical equivalence and bioequivalence rather than repeating full efficacy trials. A materially different formulation, absorption enhancer, device, or indication may require additional clinical or pharmacokinetic evidence under a 505(b)(2) strategy.

Which excipients are most likely to improve salmon calcitonin nasal absorption?

Mucoadhesive polymers, chitosan derivatives, cyclodextrins, fatty-acid salts, and selected surfactant systems are plausible development categories. Their value depends on increased exposure without unacceptable local irritation or variability.

Can an authorized generic extend Miacalcin market life?

An authorized generic can preserve commercial participation and improve price competitiveness, but it does not extend expired patent or regulatory exclusivity. Its value depends on manufacturing cost, supply reliability, distribution, and the remaining demand for salmon calcitonin.

References

1. Novartis Pharmaceuticals Corporation. (2014). Miacalcin injection prescribing information. U.S. Food and Drug Administration.

2. Novartis Pharmaceuticals Corporation. (2014). Miacalcin nasal spray prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Amendments. FDA.

4. European Medicines Agency. (2012). European Medicines Agency recommends limiting long-term use of calcitonin medicines. EMA.